Laos study aims to wipe out stomach cancer by targeting common gut bug
NCT ID NCT07340593
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study in Laos tested over 1,200 adults for H. pylori, a stomach bacteria linked to cancer. Those infected received a 14-day course of antibiotics and acid-reducing medication. The study also screened high-risk participants for early signs of stomach cancer. The goal was to see how common the infection is and whether treatment can help prevent cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- 14-day triple therapy (antibiotics and acid reducer) for H. pylori infection
- What this could lead to
- If successful, this could show that widespread H. pylori testing and treatment reduces gastric cancer risk in high-prevalence regions.
- What could go wrong
- This is a completed observational and interventional study, not a randomized controlled trial. Results may not apply to other populations, and eradication therapy can fail or cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER SCREENING are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Cancer Center
Vientiane, Capital, 0100, Laos
More trials for these conditions
Other studies related to the condition(s) this trial covers.